


Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary) 	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

U.S. PATENTS

Examiner Initial	Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date

U.S. PATENT PUBLICATIONS


Examiner Initial	Patent Application Publication Number	Publication Date	Applicant


PENDING U.S. PATENT APPLICATIONS

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
PS	WO 00/48983	08/24/2000	PCT			
PS	JP2002306130	10/22/2002	Japan			X
PS	WO 02/078616	10/10/2002	PCT			
	Int'l Search Report for PCT/US04/08474	08/18/2005	PCT			

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)						
PS		Shara, M., et al., "Dose- and Time-Dependent Effects of a Novel (-)-Hydroxycitric Acid Extract on Body Weight, Hepatic and Testicular Lipid Peroxidation, DNA Fragmentation and Histopathological Data Over a Period of 90 Days," <i>Mol Cell Biochem.</i> Dec. 2003; 254(1-2); pp. 339-346.				
		 9/29/06				




Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

U.S. PATENTS							
Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
PS		4,923,855	May 8, 1990	Jensen	1	1	
PS		4,954,492	Sep. 4, 1990	Jensen	1	1	
PS		5,194,615	Mar. 16, 1993	Jensen	1	1	
PS		5,266,560	Nov 30, 1993	Furman et al.	1	1	
PS		5,480,657	Jan 2, 1996	Ann de Wees T. Allen	1	1	
PS		5,543,405	Aug. 6, 1996	Keown et al.	1	1	
PS		5,567,424	Oct. 22, 1996	Hastings	1	1	
PS		5,612,039	Mar 18, 1997	Policappelli et al.	1	1	
PS		5,626,849	May 6, 1997	Hastings et al.	1	1	
PS		5,716,976	Feb 10, 1998	Richard K. Bernstein	1	1	
PS		5,783,603	Jul 21, 1998	Majeed et al.	1	1	
PS		5,981,510	Nov. 9, 1999	Fujiwara et al.	1	1	
PS		6,034,125	Mar 7, 2000	Malcolm N. McLeod	1	1	
PS		6,048,846	Nov. 9, 1999	Cochran	1	1	
PS		6,100,251	Aug. 8, 2000	De la Harpe et al.	1	1	
PS		6,203,819	Mar. 20, 2001	Fine	1	1	
PS		6,207,714	Mar 27, 2001	Clouatre et al.	1	1	
PS		6,217,898	Apr 17, 2001	Claudio Cavazza	1	1	
PS		6,258,848	Jul 10, 2001	I. George Fantus	1	1	
PS		6,291,533	Sep. 18, 2001	Fleishner	1	1	
PS		6,352,713	Mar. 5, 2002	Kirschner et al.	1	1	
PS		6,383,482	May 7, 2002	Wayne F. Gorsek	1	1	
PS		6,399,089	Jun 4, 2002	Yegorova et al.	1	1	

Attorney Docket No.: IHEAL-01040US1
 M:\ACraig\wp\IHEAL\1040\1040US1\IDS 2.doc

P. Spinack a/k/a/06

Form PTO-1449 (Substitute) 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.			
	Filing/Issue Date March 19, 2004		Group Art Unit 1614	

PS		6,413,545	Jul. 2, 2002	Alviar et al.			
PS		6,541,026	Apr. 1, 2003	Siskind			
PS		6,579,866	Jun. 17, 2003	McCleary			
PS		6,589,566	Jul. 8, 2003	Ueda et al.			
PS		6,638,542	Oct. 28, 2003	Nieuwenhuizen et al.			

U.S. PATENT PUBLICATIONS

Examiner Initial	Patent Application Publication Number	Publication Date	Applicant
PS	2001/0031744	Oct. 18, 2001	Kosbab
PS	2003/0220329	Nov. 27, 2003	Surwit et al.
PS	2004/0157929	Aug 12, 2004	Ohia et al.
PS	2004/0186181	Sep 23, 2004	Bagchi et al.

PENDING U.S. PATENT APPLICATIONS

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No
	60/554,653	Mar 19, 2004	Bagchi et al.	
	60/628,381	Nov 16, 2004	Bagchi et al.	
	09/463,024	Feb 15, 2002	G. Ganga-Raju	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
PS	WO 99/03464	28 Jan 1999	PCT			
PS	WO 00/12080	9 Mar 2000	PCT			

Examiner <i>P. Spivack</i>	Date Considered <i>9/29/06</i>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	

Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

PS		WO 02/078616	10 Oct 2002	PCT				
PS		EP 0 714 663	5 Jun 1996	EPO				
PS		WO 00/57729	5 Oct 2000	PCT				
PS		WO 00/48983	24 Aug 2000	PCT				

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)								
PS		Calapai, Gioacchino et al., "Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis," <i>The Journal of Clinical Investigation</i> , Vol. 104 (7), pp. 975-982 (October 1999).						
PS		Clouatre, Dallas, "Anti-Fat Nutrients," Pax Publishing, San Francisco, CA (1993).						
PS		Goldberg, Burton, "Weight Loss - An alternative Medicine Definitive Guide," AlternativeMedicine.com Books, Tiburon, California.						
PS		Kendall, Pat, "Beware of New Weight Loss Products," Food Science and Human Nutrition Specialist, Colorado State University Cooperative Extension (July 7, 1999).						
PS		Halford, Jason et al., "Separate systems for serotonin and leptin in appetite control," <i>The Finnish Medical Society Duodecim, Ann Med</i> 2000; 32: 222-232.						
PS		Heffernan, M.A., et al., "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment," <i>International Journal of Obesity</i> , Vol. 25, pp. 1442-1449 (2001).						
PS		McCarty, M.F., "Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression - an adjuvant role for chromium picolinate?," <i>Medical Hypotheses</i> , 43: 247-252 (1994).						
PS		Murray, Michael T., "Encyclopedia of Nutritional Supplements, The Essential Guide for Improving your Health Naturally,,: Prima Publishing, Random House, Inc., New York. Pp. 194-198 (1996).						
PS		Ohia, Sunny E., et al., "Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX)," <i>Molecular and Cellular Biochemistry</i> , Vol. 238, pp. 89-103, 2002.						
PS		Ohia, Sunny E., et al., "Effect of Hydroxycitric Acid on Serotonin Release from Isolated Rat Brain Cortex," <i>Research Communications in Molecular Pathology and Pharmacology</i> , Vol. 109, Nos. 3 & 4, March, April 2001, pp. 210-216.						
PS		Palmeri, Denise, "Metabolife, Metabolite and Chitoslim: Safe Bets for Losing Weight?," ext.colostate.edu, May 2002 pp. 1-4						
PS		Roy, Sashwati, et al., "Body Weight and Abdominal Fat Gene Expression Profile in Response to a Novel Hydroxycitric Acid-Based Dietary Supplement," <i>Gene Expression</i> , Vol. 11, pp.251-262, February 24, 2004.						

Examiner <i>P. Spivack</i>	Date Considered <i>9/29/06</i>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	

Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

PS	Shara, Michael, et al., "Physico-chemical properties of a novel (--)hydroxycitric acid extract and its effect on body weight, selected organ weights, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological changes over a period of 90 days," <i>Molecular and Cellular Biochemistry</i> , Vol. 260, pp. 171-186, 3 October 2003.
PS	Tolbert, L.M. et al., "Serotonin induces mapk activation in primary cultures of cortical neurons," <i>Division of Molecular Psychiatry, Yale University, New Haven, CT, USA</i>
PS	Verghese, James, "(-)-Hydroxycitrates - The usefulness of (-)-hydroxycitric acid as an obesity regulator is attracting more attention from the food & pharmaceutical industry. Can it be called an ingredient for functional foods?," <i>The World of Ingredients</i> .
PS	Yang, et al., "The synthesis aninal experiments and preliminary clinical trial of chromium (III)-nicotinicacid-amino acids mixed ligand complexes," Database CAPLUS, Sch. Pharm, West China Univ. Med. Sci., (Chengdu, China), AN 1988:542370.
PS	AIM Metabolite (1999) AIM International, Inc.
PS	Chromium, http://www.supplementdirect.com/research/chromium.html , pp. 1-13
PS	Herbs and Weight Loss FAQ's; http://herbsforhealth.about.com/library , pp. 1-3
PS	Evaluating Natural Weight Loss Supplements, http://altmedicine.about.com/library/weekly ; pp. 1-8

Examiner <i>P. Spivack</i>	Date Considered <i>9/29/06</i>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0VKH-103711		APPLICATION NO. 10/805,129		
				Debasis Bagchi et al.				
				FILING 3/19/2004		GROUP ART 1614		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
PS		US 6,482,858 B1	11/19/2002	Cloutre et al	514	574		
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
PS		Role of fatty acid synthesis in the control of insulin-stimulated glucose utilization by rat adipocytes by Susan K. Fried, Marcelle Lavau and F. Xavier Pi-Sunyer, Journal of Lipid Research, Volume 22 (1981) .						
PS		Implication of Steroid Saponins and Sapogenins in the Hypocholesterolemic Effect of Fenugreek by Yves Sauvaire, Gerald Ribes, Jean-Claude Baccou and Marie-Madeleine Loubalieires-Mariani, Lipids Volume 26 (1991).						
EXAMINER				DATE CONSIDERED				
P. Spivack				9/29/06				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) OVKH-103711	Application Number 10/805,129
		Applicant(s) Debasis Bagchi et al.	
		Filing Date 3/19/2004	Group Art Unit 1614
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
PS	Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic by C.G. Sheda & K.T. Augusti, Indian Journal of Experimental Biology Volume 30 (1992).		
PS	More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling by S. Chen, A. Ogawa, M. Ohneda, R.H. Unger, D.W. Foster and J.D. McGarry, http://diabetes.diabetesjournals.org (1994).		
PS	More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling, by S. Chen, A. Ogawa, M. Ohneda, R.H. Unger, D.W. Foster, J.D. McGarry, http://www.ncbi.nlm.nih.gov (1994).		
PS	Effects of chromium and guar on sugar-induced hypertension in rats, by H.G. Preuss, J.A. Gondal, E. Bustos, N. Bushehri, S. Lieberman, N.A. Brayden, M.M. Polansky and R.A. Anderson, Clinical Nephrology, Volume 44, No. 3 (1995).		
PS	New Information on (-)-Hydroxycitric Acid/HCA, by Dallas Cloutre, Ph.D., Cloutre Consulting Group (1995)		
PS	Current Zinc Intake and Risk of Diabetes and Coronary Artery Disease and Factors Associated with Insulin Resistance in Rural and Urban Populations of North India, by Ram B. Singh, M.D., Mohammad A. Niaz, PhD, Shanti S. Rastogo, M.D., Sarita Bajaj, Zhang Gaoli and Zhu Shoumin, PhD, Journal of the American College of Nutrition Volume 17, No. 6 (1998).		
PS	Toward a Wholly Nutritional Therapy for Type 2 Diabetes by M.F. McCarty, http://www.sciencedirect.com (2000).		
PS	Clinical Study on Ephedra-Free Super Citrimax Published in Nutrition Research (2004).		
PS	Researchers Reveal the Beauty of Super CitriMax - Again, Inter Health (2004).		
	The Diet and Health Benefits of HCA (Hydroxycitric Acid) How This All-Natural Diet Aid Promotes Weight Loss and Inhibits Fat Production, by Dallas Cloutre, Ph.D. and Michael Rosenbaum, M.D., A Good Health Guide (undated)		
EXAMINER	DATE CONSIDERED		
P. Apivack	9/29/06		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			